A Canadian Psychedelic Survey (CPS) co-sponsored by SABI Mind, MAPS PBC and Psygen Industries recently released the results of a survey on the characteristics, patterns of use and access to psychedelic drugs.

Developed in collaboration with clinicians and academic researchers from renowned universities, the 655-question survey aims to collect real-world evidence on psychedelics use in Canada.

The CPS focused on the use of 11 psychedelics: ayahuasca, DMT or 5-MeO-DMT, iboga or ibogaine, LSD or acid, MDMA or MDA, mescaline, psilocybin, and salvia divinorum.

Additional data was collected on users and patterns of personal and therapeutic use, and the association between psychedelics and headaches/migraines, mental health, music, mindfulness practices, and use of alcohol, tobacco, and other drugs.

Participants reported a range of sources of access within the country’s current legal framework and an interest in sourcing psychedelic drugs through more formal regulated channels.

Data collected anonymously from 2045 respondents over the age of 19 with an average age of 38, of whom 56% were female, showed:

• Psilocybin, MDMA and LSD are the most commonly used psychedelics.

• Psilocybin was used at least once by 92.3% and in the past year by 59.1% of respondents.

• MDMA and LSD were used by over 60% at least once and by 25% in the past year.

• Ibogaine was the least consumed at just 2.3% and consumed by less than 1% in the past year.

• Psychedelics use is primarily motivated by fun (76.5%), self-exploration (73.3%), general mental well-being (62.4%), and personal growth (60.5%), although some advocate using it for the sake of it reduce the use of prescription drugs (11.2%). ) or non-prescription (10.6%) substances.

• Over 90% of respondents used a trippy dose of psychedelics, while 6.6% microdosed.

• 74.9% of respondents approved of using psychedelics in the past year, with 67.7% using them less than once a month.

• 82% of participants…